SAR339375
Total Payments
$22,100
Transactions
18
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $22,100 | 18 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22,100 | 18 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| PD-RG012-06-Target population-Alport Syndrome-Renal bx | SANOFI US SERVICES INC. | $16,528 | 0 |
| A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport Syndrome | SANOFI US SERVICES INC. | $5,572 | 0 |
Top Doctors Receiving Payments for SAR339375
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Cypress, TX | $22,100 | 18 |
Ad
Manufacturing Companies
- SANOFI US SERVICES INC. $22,100
Product Information
- Type Drug
- Total Payments $22,100
- Total Doctors 0
- Transactions 18
About SAR339375
SAR339375 is a drug associated with $22,100 in payments to 0 healthcare providers, recorded across 18 transactions in the CMS Open Payments database. The primary manufacturer is SANOFI US SERVICES INC..
Payment data is available from 2019 to 2019. In 2019, $22,100 was paid across 18 transactions to 0 doctors.
The most common payment nature for SAR339375 is "Unspecified" ($22,100, 100.0% of total).
SAR339375 is associated with 2 research studies, including "PD-RG012-06-Target population-Alport Syndrome-Renal bx" ($16,528).